Ftse Mib
35.090,23
-0,64%
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
94.345,87
-0,38%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Zevra Therapeutics Inc (ZVRA) Zevra Therapeutics Inc (ZVRA) Notizie

ZVRA

Zevra Therapeutics (ZVRA)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ZVRA
DataOraFonteTitoloSimboloCompagnia
17/12/202413:30GlobeNewswire Inc.Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024NASDAQ:ZVRAZevra Therapeutics Inc
06/12/202423:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
06/12/202423:00GlobeNewswire Inc.Zevra Therapeutics Announces Organizational ChangesNASDAQ:ZVRAZevra Therapeutics Inc
26/11/202413:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
21/11/202422:51GlobeNewswire Inc.Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
14/11/202422:53Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ZVRAZevra Therapeutics Inc
14/11/202419:00Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ZVRAZevra Therapeutics Inc
13/11/202422:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
12/11/202422:05GlobeNewswire Inc.Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
11/11/202422:36GlobeNewswire Inc.Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
06/11/202413:30GlobeNewswire Inc.Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13NASDAQ:ZVRAZevra Therapeutics Inc
31/10/202412:30GlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024NASDAQ:ZVRAZevra Therapeutics Inc
16/10/202422:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
10/10/202413:30GlobeNewswire Inc.Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLCNASDAQ:ZVRAZevra Therapeutics Inc
09/10/202415:00GlobeNewswire Inc.NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
24/09/202413:30GlobeNewswire Inc.Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024NASDAQ:ZVRAZevra Therapeutics Inc
20/09/202418:08GlobeNewswire Inc.Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
06/09/202414:30GlobeNewswire Inc.Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumNASDAQ:ZVRAZevra Therapeutics Inc
13/08/202422:05GlobeNewswire Inc.Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:ZVRAZevra Therapeutics Inc
13/08/202411:45IH Market NewsU.S. Futures Climb Before Inflation Data; Oil Slips on OPEC Demand CutNASDAQ:ZVRAZevra Therapeutics Inc
09/08/202422:54Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ZVRAZevra Therapeutics Inc
09/08/202406:00GlobeNewswire Inc.Zevra Therapeutics Announces Pricing of Underwritten Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
08/08/202422:01GlobeNewswire Inc.Zevra Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:ZVRAZevra Therapeutics Inc
07/08/202415:34GlobeNewswire Inc.Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
02/08/202423:50GlobeNewswire Inc.FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
30/07/202414:38GlobeNewswire Inc.Zevra Therapeutics to Report Second Quarter 2024 Financial ResultsNASDAQ:ZVRAZevra Therapeutics Inc
12/07/202422:23Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:ZVRAZevra Therapeutics Inc
09/07/202415:00GlobeNewswire Inc.Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
25/06/202413:30GlobeNewswire Inc.Zevra Therapeutics Expands Executive Leadership TeamNASDAQ:ZVRAZevra Therapeutics Inc
18/06/202413:30GlobeNewswire Inc.Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle DisordersNASDAQ:ZVRAZevra Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ZVRA

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
IVG
Iveco Group NV
BIT
CPR
Davide Campari
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
RACE
Ferrari NV
BIT
BAMI
Banco BPM
BIT
SPM
Saipem
BIT
TIT
Telecom Italia
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network